Filing Flows › Vivos Therapeutics (VVOS) › Q1 2026 › vs Q4 2025
Vivos Therapeutics (VVOS) Q1 2026 vs Q4 2025 (quarter over quarter)
Vivos Therapeutics's revenue rose $1.3M (+34%) from $3.8M in Q4 2025 to $5.1M in Q1 2026.
Vivos Therapeutics, Q1 2026: revenue $5.1M (+70% year over year), operating margin -128.7%, net loss $7.8M, operating cash flow −$6.0M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $5.1M | $3.8M | $1.3M | +34% |
| Net loss | $7.8M | $6.9M | $857K | +12% |
| Costs & expenses | $12.9M | $10.8M | $2.1M | +20% |
| Operating costs | $11.8M | $10.2M | $1.6M | +15% |
| Interest & other, net | $1.1M | $572K | $564K | +99% |
| Cost of revenue | $2.1M | $836K | $1.2M | +149% |
| Sales & marketing | $249K | $382K | −$133K | -35% |
| General & admin | $9.0M | $8.5M | $425K | +5% |
| Other operating costs | $454K | $442K | $12K | +3% |
| Operating cash sources | $7.8M | $6.9M | $857K | +12% |
| Depreciation & amortization | $454K | $442K | $12K | +3% |
| Share-based compensation | $151K | $47K | $104K | +221% |
| Working capital & other | $1.1M | $2.6M | −$1.5M | -56% |
| Cash used in operations | $6.0M | $3.8M | $2.2M | +58% |
| Net loss absorbed | $7.8M | $6.9M | $857K | +12% |
Questions
How much did Vivos Therapeutics's revenue grow quarter over quarter in Q1 2026?
Vivos Therapeutics's revenue rose $1.3M (+34%) from $3.8M in Q4 2025 to $5.1M in Q1 2026.